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Abstract: Background  – Atrial fibrillation (AF) and heart failure (HF) carry a poor prognosis in
acute ischaemic stroke (AIS). The impact of revascularisation therapies on outcomes in
these patients is not fully understood.  
Methods  –National Inpatient Sample (NIS) AIS admissions (January 2004-September
2015) were included (n=4,597,428). Logistic regressions analysed the relationship
between exposures (neither AF nor HF-reference, AF-only, HF-only, AF+HF) and
outcomes (in-hospital mortality, length-of-stay >median and moderate-to-severe
disability on discharge), stratifying by receipt of intravenous thrombolysis (IVT) or
endovascular thrombectomy (ET).
Results  - 69.2% patients had neither AF nor HF, 16.5% had AF-only, 7.5% had HF-
only and 6.7% had AF+HF. 5.04% and 0.72% patients underwent IVT and/or ET,
respectively. AF-only and HF-only were each associated with 75-85% increase in the
odds of in-hospital mortality. AF+HF was associated with greater than two-fold
increase in mortality. Patients with AF-only, HF-only or AF+HF undergoing IVT had
better or at least similar in-hospital outcomes compared to their counterparts not
undergoing IVT, except for prolonged hospitalisation. Patients undergoing ET with AF-
only, HF-only or AF+HF had better (in-hospital mortality, discharge disability, all-cause
bleeding) or at least similar (length-of-stay) outcomes to their counterparts not
undergoing ET. Compared to AIS patients without AF, AF patients had approximately
50% and more than two-fold increases in the likelihood of receiving IVT or ET,
respectively.
Conclusions  –We confirmed the combined and individual impact of co-existing AF or
HF on important patient-related outcomes. Revascularisation therapies improve these
outcomes significantly in patients with these comorbidities.




Response to Reviewers: 28 August 2020
Professor Paolo G. Camici
Editor-in-Chief
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
International Journal of Cardiology
Subject: Revision of Manuscript ID IJC_2020_1732_R2
Dear Professor Camici,
We thank the editors for giving us the opportunity to re-submit a revised version of an
original article entitled “Revascularisation Therapies Improve the Outcomes of
Ischemic Stroke Patients with Atrial Fibrillation and Heart Failure” to be considered for
publication in the International Journal of Cardiology.
We provide below point-by-point responses to the comments made by the reviewer.
We also attached a tracked version of our manuscript. Given that this is a third
revision, we have tracked our changes on a clean version of the manuscript submitted
for the second revision.
On behalf of all co-authors, I would like to take the opportunity to thank the Editorial
Board for considering our paper and the reviewers for their helpful comments.
We sincerely hope that the revised version will satisfy the reviewers and the editors,
and that the revised manuscript will be acceptable in the current form. We look forward
to hearing from you.
Yours sincerely,
Professor Phyo K Myint (corresponding author)
Clinical Chair in Old Age Medicine
For and on behalf of all co-authors
 
We have highlighted the changes in the text, where appropriate, as follows: (additions
in blue, deletions in red):.
Comments from reviewers:
REVIEWER 5
- This manuscript is a large-scale cohort study of acute ischemic stroke patients.
Implication on revascularization (Intravenous thrombolysis or endovascular
thrombectomy) should be minimized in the conclusion because of the following
reasons.
1) This is not a prospective intervention study, but a observational study
Response: Thank you very much for taking the time to review our manuscript. We
appreciate and share the reviewer’s concerns about drawing clinical conclusions
regarding the use of revascularisation therapies in these patient groups based on an
observational study. We have thus modified the conclusions drawn from this study to
reflect the fact that while our results drawn from observational data are encouraging,
no direct clinical recommendations can be made based on these without further clinical
trial data.
Under ABSTRACT, page 2, lines 21-24:
“Conclusions –We confirmed the combined and individual impact of co-existing AF or
HF on important patient-related outcomes. Revascularisation therapies improve these
outcomes significantly in patients with these comorbidities and should be offered
routinely unless contra-indicated.”
Under CONCLUSIONS, page 17, lines 16-24:
“In this study of real-world data, AIS patients with co-morbid AF or HF undergoing IVT
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
had either better or comparable in-hospital adverse outcomes than their counterparts
not undergoing IVT. There were no positive associations between AF or HF and
adverse in-hospital outcomes amongst AIS patients undergoing ET. Therefore, Cco-
morbid AF and/or HF should not solely represent a criterion against delivering IVT
therapy to AIS patients. Furthermore,, while ET may be an effective therapeutic
strategy to manage the excess risk of adverse short-term outcomes associated with AF
and/or HF in AIS. Therefore, revascularisation therapies should be considered and
offered routinely in acute ischemic stroke patients with these comorbidities unless
contra-indicated.”
The study HIGHLIGHTS have also been updated accordingly:
“
•We examined the impact of IVT and ET on stroke outcomes in patients with AF and
HF
•Estimates were calculated for all US ischemic stroke admissions between 2004-2015
•AF and HF were associated with significantly worse in-hospital outcomes
•IVT/ET reduced the AF/HF-associated excess odds of adverse in-hospital outcomes
•IVT/ET should be offered routinelyconsidered in ischemic stroke patients with AF/HF if
not contraindicated.
”
2) The authors did not compare effect sizes of revascularization therapy on outcomes
among different patient groups. Therefore, it is unclear at present whether
revascularization is more effective in a specific patient group of AF(+)HF(+) compared
with AF(-)HF(-).
Response: Thank you for highlighting this issue. We share the reviewer’s concern that
a direct comparison between the effect sizes of the IVT/ET interaction terms across the
different exposure groups is warranted. Such direct comparisons can be performed by
comparing the magnitudes of each IVT/ET interaction terms. We have thus added the
following supplementary table displaying the odds ratios and 95% confidence intervals
of the IVT and ET interaction terms with each one of the three exposure groups:
Supplementary Table 7. Interaction terms between revascularisation therapy
(intravenous thrombolysis or endovascular thrombectomy) and the relationship




In-Hospital Mortality0.75 (0.67-0.84)0.75 (0.62-0.89)0.65 (0.56-0.76)
Los > Median1.23 (1.14-1.32)1.07 (0.95-1.20)1.16 (1.04-1.30)
Discharge Disability0.96 (0.89-1.04)0.92 (0.81-1.05)0.95 (0.82-1.10)
All-cause Bleeding0.87 (0.78-0.97)0.89 (0.74-1.07)0.75 (0.64-0.88)
ET Interaction Term
In-Hospital Mortality0.40 (0.32-0.50)0.41 (0.27-0.61)0.34 (0.25-0.47)
Los > Median0.70 (0.58-0.83)0.96 (0.69-1.34)0.65 (0.51-0.83)
Discharge Disability0.59 (0.48-0.74)0.75 (0.49-1.15)0.76 (0.52-1.11)
All-cause Bleeding0.56 (0.45-0.69)0.54 (0.37-0.78)0.52 (0.39-0.69)
IVT – Intravenous Thrombolysis, ET – Endovascular Thrombectomy
All regression models were adjusted for age, sex, ethnicity, smoking status, hospital
characteristics (bed size, location, teaching status), 29 Elixhauser co-morbidities and
other co-morbidities (myocardial infarction, coronary heart disease, other arrhythmias,
dyslipidaemia, previous transient ischaemic attack, dementia, shock), previous
coronary artery bypass surgery, and family history of cerebrovascular events or
ischaemic heart disease.
Statistically significant (P < 0.01) results are displayed in Bold
Furthermore, the RESULTS and DISCUSSION sections have been updated
accordingly.
Under RESULTS, page 10, lines 8-24 and page 9 lines 1-16:
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
“Figure 3 and Supplementary Table 6 detail the results of the primary analyses.
Supplementary Table 7 details the effect size of the interactions between
revascularisation therapies and the relationship between the exposures of interest and
in-hospital outcomes. Amongst patients not receiving IVT, AF only (1.90 (1.83-1.96)),
HF only ((1.81 (1.72-1.89)) and AF+HF (2.63 (2.51-2.75)) were associated with
increased odds of in-hospital mortality. Amongst patients receiving IVT, AF only (1.43
(1.28-1.58)), HF only (1.35 (1.13-1.60)) and AF+HF (1.72 (1.49-1.99)) were associated
with increases in the odds of in-hospital mortality which were significantly lower than
the increases recorded amongst patients not undergoing IVT (P value for interaction
<0.001). Thus, IVT was associated with 25% decreases in the AF-only and HF-only
associated increases in the odds of in-hospital mortality, while a 35% decrease was
recorded in AF+HF patients. AF only, HF only and AF+HF were associated with
significant increases in the odds of prolonged hospitalisation amongst both the IVT and
no IVT groups. The increases in the odds of prolonged hospitalisation associated with
AF only and AF+HF, but not HF only, were significantly higher amongst patients
undergoing IVT than in those not undergoing IVT (P value for interaction ≤0.001). AF
only, HF only and AF+HF were associated with significant increases in the odds of
moderate-to-severe disability on discharge amongst both the IVT and no IVT groups.
AF only, HF only and AF+HF were associated with significant increases in the odds of
all-cause bleeding amongst both the IVT and no IVT groups. The increases in the odds
of all-cause bleeding associated with AF only and AF+HF were significantly lower
amongst patients undergoing IVT than in those not undergoing IVT (P value for
interaction ≤0.001).”
Amongst patients not receiving ET, AF only (1.88 (1.82-1.95)), HF only ((1.79 (1.71-
1.88)) and AF+HF (2.58 (2.47-2.70)) were associated with increased odds of in-
hospital mortality. Amongst patients receiving ET, AF only (0.75 (0.60-0.93)) was
associated with decreased odds of in-hospital mortality. There were no associations
between HF only (0.73 (0.49-1.10)) or AF+HF (0.88 (0.64-1.12)) and in-hospital
mortality amongst patients undergoing ET. Thus, ET was associated with 60%
decreases in the AF-only and HF-only associated increases in the odds of in-hospital
mortality, while a  66% decrease was recorded in AF+HF patients. Amongst patients
not receiving ET, AF only, HF only and AF+HF were associated with increased odds of
prolonged hospitalisation, moderate-to-severe disability on discharge and all-cause
bleeding. There were no associations between the exposure groups and prolonged
hospitalisation, moderate-to-severe disability on discharge or all-cause bleeding
amongst patients undergoing ET.”
Under DISCUSSION, page 12 lines 20-24 and page 13 lines 1-25:
“IVT therapy was associated with significant reductions in the excess odds of in-
hospital mortality and all-cause bleeding associated with AF and AF+HFall exposure
groups. Nevertheless, higher reductions in excess in-hospital mortality associated with
IVT were recorded in patients with AF+HF than in those with either AF only or HF only.
IVT was nevertheless associated with an increase in the excess odds of prolonged
hospitalisation associated with AF and AF+HF. Post-hoc analyses aimed at further
characterising this finding revealed that this may be because IVT was associated with
higher odds of bleeding in all AIS patients, but the IVT-associated excess odds of
bleeding were significantly higher amongst patients with neither AF nor HF than in
those with AF only or AF+HF. Given that prior anticoagulation is a contra-indication to
IVT36, this finding may be due to the fact that only AF patients without prior
anticoagulant therapy may have been offered IVT, resulting in an overall lower
bleeding risk amongst these patients. IVT therapy was associated with significant
reductions in the excess odds of all-cause bleeding associated with AF and AF+HF.
Our results also show that AIS patients with co-morbid HF undergoing IVT were at
lower odds of in-hospital mortality and similar odds of discharge disability and all-cause
bleeding compared to their counterparts not undergoing IVT. Out of all the studied
outcomes in relation to IVT therapy, discharge disability showed the weakest
associations. However, it is important to consider when interpreting these results that
we defined discharge disability as a proxy based on discharge destination.
ET was associated with significant reductions in the AF- and AF+HF-associated
excess odds of in-hospital mortality, discharge disability and all-cause bleeding.
Furthermore, ET was also associated with significant reductions in the HF-associated
excess odds of in-hospital mortality and all-cause bleeding. Similarly as with IVT,
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
higher reductions in excess in-hospital mortality associated with ET were recorded in
patients with AF+HF than in those with either AF only or HF only.  Amongst AIS
patients undergoing ET, AF was associated with decreased odds of in-hospital
mortality whilst there were no other associations between AF, HF or AF+HF and any
other pre-specified outcomes. Post-hoc analyses revealed that these findings may be
because ET disproportionately increased the odds of adverse outcomes amongst AIS
patients with neither AF nor HF, but not amongst those with AF or HF. Having adjusted
our analyses by age and co-morbidity profile, it is reasonable to hypothesise that.”
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
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Professor Paolo G. Camici 
Editor-in-Chief  
International Journal of Cardiology 
  
Subject: Revascularisation Therapies Improve the Outcomes of Ischemic Stroke Patients with Atrial Fibrillation and Heart 
Failure 
 
Dear Professor Camici, 
We are pleased to submit an original research article entitled “Revascularisation Therapies Improve the Outcomes of Ischemic 
Stroke Patients with Atrial Fibrillation and Heart Failure” to be considered for publication in the International Journal of 
Cardiology.  
 
Both atrial fibrillation (AF) and heart failure (HF) are associated not only with increased incidence of acute ischaemic stroke, but also 
with poor post-ischaemic stroke outcomes. Furthermore, we have previously shown that patients with co-existing AF and HF experience 
significantly worse post-stroke in-hospital outcomes compared to patients with either AF alone or HF alone, thus suggesting that the 
associations between the two co-morbidities and poor outcomes are cumulative in the short term. Furthermore, the effects of AF and HF 
on the outcomes of ischaemic stroke patients undergoing intravenous thrombolysis or endovascular thrombectomy are not fully 
understood.  
 
In this study, we aimed to answer these questions by analysing all acute ischaemic stroke admissions from the US National Inpatient 
Sample between 2004 and 2015, yielding a sample representative of more than 4.5 million admissions. We defined the exposure groups 
by stratifying the sample into 4 mutually exclusive groups: patients with neither AF nor HF, those with AF only, those with HF only or 
those with both AF and HF. We compared the outcomes between these groups performing further stratifications by whether patients 
underwent intravenous thrombolysis or endovascular thrombectomy during their hospital admission. We have found that acute ischaemic 
stroke patients with co-morbid AF and/or HF undergoing intravenous thrombolysis had either better or at least comparable in-hospital 
outcomes to their counterparts not undergoing thrombolysis. Furthermore, there were no positive associations between AF or HF and 
adverse in-hospital outcomes amongst AIS patients undergoing ET. We conclude that revascularisation therapies should be considered 
and offered routinely in acute ischemic stroke patients with these comorbidities unless contra-indicated and that endovascular 
thrombectomy may be an effective therapeutic strategy to manage the excess risk of adverse short-term outcomes associated with AF 
and/or HF in acute ischaemic stroke.  
 
We believe that our findings will be of interest to the readership of the International Journal of Cardiology and also relevant to 
researchers, clinicians and the public.  
 
All authors have read and approved the submitted manuscript, the manuscript has not been submitted elsewhere nor published elsewhere 
in whole or in part, except as an abstract. We look forward to hearing from you.  
 
 
Yours sincerely,  
  
Professor Phyo K Myint (corresponding author); Clinical Chair in Old Age Medicine  






28 August 2020 
 
Professor Paolo G. Camici 
Editor-in-Chief  
International Journal of Cardiology  
 
Subject: Revision of Manuscript ID IJC_2020_1732_R2 
 
Dear Professor Camici, 
 
 
We thank the editors for giving us the opportunity to re-submit a revised version of an original 
article entitled “Revascularisation Therapies Improve the Outcomes of Ischemic Stroke 
Patients with Atrial Fibrillation and Heart Failure” to be considered for publication in the 
International Journal of Cardiology.  
 
We provide below point-by-point responses to the comments made by the reviewer.  
 
We also attached a tracked version of our manuscript. Given that this is a third revision, we have 
tracked our changes on a clean version of the manuscript submitted for the second revision. 
 
On behalf of all co-authors, I would like to take the opportunity to thank the Editorial Board for 
considering our paper and the reviewers for their helpful comments.  
 
We sincerely hope that the revised version will satisfy the reviewers and the editors, and that the 
revised manuscript will be acceptable in the current form. We look forward to hearing from you.  
 
 
Yours sincerely,  
  
Professor Phyo K Myint (corresponding author) 
Clinical Chair in Old Age Medicine  










We have highlighted the changes in the text, where appropriate, as follows: (additions in blue, 
deletions in red):. 
 
Comments from reviewers: 
REVIEWER 5 
- This manuscript is a large-scale cohort study of acute ischemic stroke patients. 
Implication on revascularization (Intravenous thrombolysis or endovascular 
thrombectomy) should be minimized in the conclusion because of the following reasons. 
1) This is not a prospective intervention study, but a observational study 
Response: Thank you very much for taking the time to review our manuscript. We appreciate 
and share the reviewer’s concerns about drawing clinical conclusions regarding the use of 
revascularisation therapies in these patient groups based on an observational study. We have thus 
modified the conclusions drawn from this study to reflect the fact that while our results drawn 
from observational data are encouraging, no direct clinical recommendations can be made based 
on these without further clinical trial data. 
 
Under ABSTRACT, page 2, lines 21-24: 
 
“Conclusions –We confirmed the combined and individual impact of co-existing AF or HF on 
important patient-related outcomes. Revascularisation therapies improve these outcomes 
significantly in patients with these comorbidities and should be offered routinely unless contra-
indicated.” 
 
Under CONCLUSIONS, page 17, lines 16-24: 
 
“In this study of real-world data, AIS patients with co-morbid AF or HF undergoing IVT had 
either better or comparable in-hospital adverse outcomes than their counterparts not undergoing 
IVT. There were no positive associations between AF or HF and adverse in-hospital outcomes 
amongst AIS patients undergoing ET. Therefore, Cco-morbid AF and/or HF should not solely 
represent a criterion against delivering IVT therapy to AIS patients. Furthermore,, while ET may 
be an effective therapeutic strategy to manage the excess risk of adverse short-term outcomes 
associated with AF and/or HF in AIS. Therefore, revascularisation therapies should be 
considered and offered routinely in acute ischemic stroke patients with these comorbidities 
unless contra-indicated.” 
 






 We examined the impact of IVT and ET on stroke outcomes in patients with AF and HF 
 Estimates were calculated for all US ischemic stroke admissions between 2004-2015 
 AF and HF were associated with significantly worse in-hospital outcomes 
 IVT/ET reduced the AF/HF-associated excess odds of adverse in-hospital outcomes 




2) The authors did not compare effect sizes of revascularization therapy on outcomes 
among different patient groups. Therefore, it is unclear at present whether 
revascularization is more effective in a specific patient group of AF(+)HF(+) compared 
with AF(-)HF(-). 
Response: Thank you for highlighting this issue. We share the reviewer’s concern that a direct 
comparison between the effect sizes of the IVT/ET interaction terms across the different 
exposure groups is warranted. Such direct comparisons can be performed by comparing the 
magnitudes of each IVT/ET interaction terms. We have thus added the following supplementary 
table displaying the odds ratios and 95% confidence intervals of the IVT and ET interaction 
terms with each one of the three exposure groups: 
 
Supplementary Table 7. Interaction terms between revascularisation therapy (intravenous thrombolysis or 
endovascular thrombectomy) and the relationship between the exposures of interest and in-hospital outcomes (also 
see Supplementary Table 6). 
 AF only HF only AF+HF 
 IVT Interaction Term 
In-Hospital Mortality 0.75 (0.67-0.84) 0.75 (0.62-0.89) 0.65 (0.56-0.76) 
Los > Median 1.23 (1.14-1.32) 1.07 (0.95-1.20) 1.16 (1.04-1.30) 
Discharge Disability 0.96 (0.89-1.04) 0.92 (0.81-1.05) 0.95 (0.82-1.10) 
All-cause Bleeding 0.87 (0.78-0.97) 0.89 (0.74-1.07) 0.75 (0.64-0.88) 
 ET Interaction Term 
In-Hospital Mortality 0.40 (0.32-0.50) 0.41 (0.27-0.61) 0.34 (0.25-0.47) 
Los > Median 0.70 (0.58-0.83) 0.96 (0.69-1.34) 0.65 (0.51-0.83) 
Discharge Disability 0.59 (0.48-0.74) 0.75 (0.49-1.15) 0.76 (0.52-1.11) 
All-cause Bleeding 0.56 (0.45-0.69) 0.54 (0.37-0.78) 0.52 (0.39-0.69) 
 
IVT – Intravenous Thrombolysis, ET – Endovascular Thrombectomy 
All regression models were adjusted for age, sex, ethnicity, smoking status, hospital characteristics (bed size, 
location, teaching status), 29 Elixhauser co-morbidities and other co-morbidities (myocardial infarction, coronary 
heart disease, other arrhythmias, dyslipidaemia, previous transient ischaemic attack, dementia, shock), previous 
coronary artery bypass surgery, and family history of cerebrovascular events or ischaemic heart disease. 







Furthermore, the RESULTS and DISCUSSION sections have been updated accordingly.  
 
Under RESULTS, page 10, lines 8-24 and page 9 lines 1-16: 
 
“ Figure 3 and Supplementary Table 6 detail the results of the primary analyses. 
Supplementary Table 7 details the effect size of the interactions between revascularisation 
therapies and the relationship between the exposures of interest and in-hospital outcomes. 
Amongst patients not receiving IVT, AF only (1.90 (1.83-1.96)), HF only ((1.81 (1.72-1.89)) and 
AF+HF (2.63 (2.51-2.75)) were associated with increased odds of in-hospital mortality. Amongst 
patients receiving IVT, AF only (1.43 (1.28-1.58)), HF only (1.35 (1.13-1.60)) and AF+HF (1.72 
(1.49-1.99)) were associated with increases in the odds of in-hospital mortality which were 
significantly lower than the increases recorded amongst patients not undergoing IVT (P value for 
interaction <0.001). Thus, IVT was associated with 25% decreases in the AF-only and HF-only 
associated increases in the odds of in-hospital mortality, while a 35% decrease was recorded in 
AF+HF patients. AF only, HF only and AF+HF were associated with significant increases in the 
odds of prolonged hospitalisation amongst both the IVT and no IVT groups. The increases in the 
odds of prolonged hospitalisation associated with AF only and AF+HF, but not HF only, were 
significantly higher amongst patients undergoing IVT than in those not undergoing IVT (P value 
for interaction ≤0.001). AF only, HF only and AF+HF were associated with significant increases 
in the odds of moderate-to-severe disability on discharge amongst both the IVT and no IVT 
groups. AF only, HF only and AF+HF were associated with significant increases in the odds of 
all-cause bleeding amongst both the IVT and no IVT groups. The increases in the odds of all-
cause bleeding associated with AF only and AF+HF were significantly lower amongst patients 
undergoing IVT than in those not undergoing IVT (P value for interaction ≤0.001).” 
Amongst patients not receiving ET, AF only (1.88 (1.82-1.95)), HF only ((1.79 (1.71-
1.88)) and AF+HF (2.58 (2.47-2.70)) were associated with increased odds of in-hospital 
mortality. Amongst patients receiving ET, AF only (0.75 (0.60-0.93)) was associated with 
decreased odds of in-hospital mortality. There were no associations between HF only (0.73 
(0.49-1.10)) or AF+HF (0.88 (0.64-1.12)) and in-hospital mortality amongst patients undergoing 
ET. Thus, ET was associated with 60% decreases in the AF-only and HF-only associated 
increases in the odds of in-hospital mortality, while a  66% decrease was recorded in AF+HF 
patients. Amongst patients not receiving ET, AF only, HF only and AF+HF were associated with 
increased odds of prolonged hospitalisation, moderate-to-severe disability on discharge and all-
cause bleeding. There were no associations between the exposure groups and prolonged 
hospitalisation, moderate-to-severe disability on discharge or all-cause bleeding amongst patients 
undergoing ET.” 
 
Under DISCUSSION, page 12 lines 20-24 and page 13 lines 1-25: 
 
“ IVT therapy was associated with significant reductions in the excess odds of in-hospital 
mortality and all-cause bleeding associated with AF and AF+HFall exposure groups. 
Nevertheless, higher reductions in excess in-hospital mortality associated with IVT were 
recorded in patients with AF+HF than in those with either AF only or HF only. IVT was 




associated with AF and AF+HF. Post-hoc analyses aimed at further characterising this finding 
revealed that this may be because IVT was associated with higher odds of bleeding in all AIS 
patients, but the IVT-associated excess odds of bleeding were significantly higher amongst 
patients with neither AF nor HF than in those with AF only or AF+HF. Given that prior 
anticoagulation is a contra-indication to IVT36, this finding may be due to the fact that only AF 
patients without prior anticoagulant therapy may have been offered IVT, resulting in an overall 
lower bleeding risk amongst these patients. IVT therapy was associated with significant 
reductions in the excess odds of all-cause bleeding associated with AF and AF+HF. Our results 
also show that AIS patients with co-morbid HF undergoing IVT were at lower odds of in-
hospital mortality and similar odds of discharge disability and all-cause bleeding compared to 
their counterparts not undergoing IVT. Out of all the studied outcomes in relation to IVT 
therapy, discharge disability showed the weakest associations. However, it is important to 
consider when interpreting these results that we defined discharge disability as a proxy based on 
discharge destination.   
ET was associated with significant reductions in the AF- and AF+HF-associated excess 
odds of in-hospital mortality, discharge disability and all-cause bleeding. Furthermore, ET was 
also associated with significant reductions in the HF-associated excess odds of in-hospital 
mortality and all-cause bleeding. Similarly as with IVT, higher reductions in excess in-hospital 
mortality associated with ET were recorded in patients with AF+HF than in those with either AF 
only or HF only.  Amongst AIS patients undergoing ET, AF was associated with decreased odds 
of in-hospital mortality whilst there were no other associations between AF, HF or AF+HF and 
any other pre-specified outcomes. Post-hoc analyses revealed that these findings may be because 
ET disproportionately increased the odds of adverse outcomes amongst AIS patients with neither 
AF nor HF, but not amongst those with AF or HF. Having adjusted our analyses by age and co-
morbidity profile, it is reasonable to hypothesise that.” 
Revascularisation Therapies Improve the Outcomes of Ischemic Stroke Patients with 
Atrial Fibrillation and Heart Failure 
Highlights 
 We examined the impact of IVT and ET on stroke outcomes in patients with AF and 
HF 
 Estimates were calculated for all US ischemic stroke admissions between 2004-2015 
 AF and HF were associated with significantly worse in-hospital outcomes 
 IVT/ET reduced the AF/HF-associated excess odds of adverse in-hospital outcomes 
 IVT/ET should be offered routinelyconsidered in ischemic stroke patients with 
AF/HF if not contraindicated. 
 Formatted: Normal, Space After:  8 pt, Tab stops:  0.5",
Left +  1.03", Left
Highlights
ABSTRACT 
Background – Atrial fibrillation (AF) and heart failure (HF) carry a poor prognosis in acute 
ischaemic stroke (AIS). The impact of revascularisation therapies on outcomes in these 
patients is not fully understood.   
Methods –National Inpatient Sample (NIS) AIS admissions (January 2004-September 2015) 
were included (n=4,597,428). Logistic regressions analysed the relationship between 
exposures (neither AF nor HF-reference, AF-only, HF-only, AF+HF) and outcomes (in-
hospital mortality, length-of-stay >median and moderate-to-severe disability on discharge), 
stratifying by receipt of intravenous thrombolysis (IVT) or endovascular thrombectomy (ET).  
Results - 69.2% patients had neither AF nor HF, 16.5% had AF-only, 7.5% had HF-only and 
6.7% had AF+HF. 5.04% and 0.72% patients underwent IVT and/or ET, respectively. AF-
only and HF-only were each associated with 75-85% increase in the odds of in-hospital 
mortality. AF+HF was associated with greater than two-fold increase in mortality. Patients 
with AF-only, HF-only or AF+HF undergoing IVT had better or at least similar in-hospital 
outcomes compared to their counterparts not undergoing IVT, except for prolonged 
hospitalisation. Patients undergoing ET with AF-only, HF-only or AF+HF had better (in-
hospital mortality, discharge disability, all-cause bleeding) or at least similar (length-of-stay) 
outcomes to their counterparts not undergoing ET. Compared to AIS patients without AF, AF 
patients had approximately 50% and more than two-fold increases in the likelihood of 
receiving IVT or ET, respectively. 
Conclusions –We confirmed the combined and individual impact of co-existing AF or HF on 
important patient-related outcomes. Revascularisation therapies improve these outcomes 
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Background – Atrial fibrillation (AF) and heart failure (HF) carry a poor prognosis in acute 2 
ischaemic stroke (AIS). The impact of revascularisation therapies on outcomes in these 3 
patients is not fully understood.   4 
Methods –National Inpatient Sample (NIS) AIS admissions (January 2004-September 2015) 5 
were included (n=4,597,428). Logistic regressions analysed the relationship between 6 
exposures (neither AF nor HF-reference, AF-only, HF-only, AF+HF) and outcomes (in-7 
hospital mortality, length-of-stay >median and moderate-to-severe disability on discharge), 8 
stratifying by receipt of intravenous thrombolysis (IVT) or endovascular thrombectomy (ET).  9 
Results - 69.2% patients had neither AF nor HF, 16.5% had AF-only, 7.5% had HF-only and 10 
6.7% had AF+HF. 5.04% and 0.72% patients underwent IVT and/or ET, respectively. AF-11 
only and HF-only were each associated with 75-85% increase in the odds of in-hospital 12 
mortality. AF+HF was associated with greater than two-fold increase in mortality. Patients 13 
with AF-only, HF-only or AF+HF undergoing IVT had better or at least similar in-hospital 14 
outcomes compared to their counterparts not undergoing IVT, except for prolonged 15 
hospitalisation. Patients undergoing ET with AF-only, HF-only or AF+HF had better (in-16 
hospital mortality, discharge disability, all-cause bleeding) or at least similar (length-of-stay) 17 
outcomes to their counterparts not undergoing ET. Compared to AIS patients without AF, AF 18 
patients had approximately 50% and more than two-fold increases in the likelihood of 19 
receiving IVT or ET, respectively. 20 
Conclusions –We confirmed the combined and individual impact of co-existing AF or HF on 21 
important patient-related outcomes. Revascularisation therapies improve these outcomes 22 
significantly in patients with these comorbidities and should be offered routinely unless 23 
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1. Introduction 1 
 Atrial fibrillation (AF) and heart failure (HF) are associated with increased incidence 2 
of acute ischaemic stroke (AIS)1,2 and post-AIS adverse outcomes3-7. Furthermore, AF and 3 
HF frequently co-exist8 and it is well documented that AIS patients with co-existing AF and 4 
HF experience worse in-hospital outcomes than their counterparts with either AF or HF 5 
alone7.  6 
 Both intravenous thrombolysis (IVT) and endovascular thrombectomy (ET)  have 7 
been shown to improve post-AIS mortality and functional outcomes9,10. The effect of AF and 8 
HF on the outcomes of AIS patients undergoing IVT or ET remains unclear. Previous small-9 
scale observational studies and retrospective analyses of trial data have yielded equivocal 10 
results on whether co-morbid AF or HF may be associated with worse11-15, similar16-19 or 11 
better20,21 outcomes in AIS patients undergoing IVT. A meta-analysis found that AF was 12 
associated with excess mortality, disability and bleeding at 90 days post-discharge amongst 13 
AIS patients undergoing IVT22. Similarly, no associations between AF23,24 or HF25 and worse 14 
outcomes after ET were found despite suggestions that cardioembolic stroke may be an 15 
independent predictor of adverse outcomes after ET26. Finally, no previous study has assessed 16 
the association between the co-existent AF and HF and post-AIS outcomes after IVT or ET.  17 
In this study, we aimed to determine whether patients with AF, HF and AF+HF have 18 
improved AIS in-hospital outcomes (mortality, length-of-stay, discharge disability and all-19 
cause bleeding) with IVT and ET.  20 





































































2. Methods 1 
This study was conducted in accordance with the principles of the Declaration of Helsinki 2 
(1975) and later amendments. The data that support the findings of this study are available 3 
from the corresponding author on reasonable request. 4 
 5 
2.1 Data source and inclusion criteria 6 
 The National Inpatient Sample (NIS) is a large publicly available database containing 7 
>7 million annual hospital admission records. The NIS contains admission records 8 
representing a 20% stratified sample of all community hospital admissions in the United 9 
States in a given timeframe. Using the provided sampling weights, the NIS data can be used 10 
to provide national estimates for the sampling population, representative of ~95% of the US 11 
population27,28. Prior to undertaking this project, all authors completed the online HCUP Data 12 
Use Agreement Training Tool. All authors also read and signed the Data Use Agreement for 13 
Nationwide Databases. As the NIS is a publicly available database with no patient 14 
identifiable information, no ethical approval was needed. Using data files containing annual 15 
admissions between 2004-2015, all records with a primary diagnosis of ischaemic stroke 16 
(International Classification of Disease – ninth edition (ICD9) codes 433.01, 433.11, 433.21, 17 
433.31, 433.8, 433.91, 434.01, 434.11 and 434.91) were extracted. Only cases admitted 18 
between January 2004-September 2015 were included due to a change in co-morbidity 19 
coding occurring after September 201527. 20 
 Figure 1 details the study population. A total of 1,005,810 admission records with a 21 
primary diagnosis of ischaemic stroke admitted between January 2004-September 2015 were 22 
extracted. After applying the exclusion criteria, a total of 952,368 records were included. 23 
Elective admissions were excluded to ensure that only admissions which were triggered by 24 





































































stroke event. After the application of sampling weights and the exclusion of strata with single 1 
sampling units, the included records were used to provide estimates for the population from 2 
which they were sampled: 4,597,428 patients admitted with a primary diagnosis of AIS. 3 
2.2 Definition of exposure, confounders and outcomes 4 
Supplementary Table 1 details the ICD9 codes utilised to extract the variables of 5 
interest. Co-morbid conditions (including AF and HF) were also identified using ICD-9 codes 6 
and represent diagnoses assigned before or during the index acute ischaemic stroke 7 
hospitalisation. AF and HF were defined using all the necessary ICD-9 codes to encompass 8 
all the possible subtypes of each disease. The Elixhauser co-morbidities were determined 9 
using the HCUP Elixhauser co-morbidity software29. The disability outcome was estimated 10 
using a previously validated method using the discharge destination as a proxy30. All records 11 
of patients who died in hospital, those who were discharged against medical advice and those 12 
discharged to an unknown destination were excluded from the analyses prior to weighting 13 
(n=54,569 (5.73%)), allowing estimates for this particular outcome to be provided for 14 
4,334,370 (95.04%) of AIS patients. ‘Routine’ discharges were classified as none-or-minimal 15 
disability on discharge, whilst discharges to ‘home health care’, ‘short-term hospital’ and 16 
‘other facilities including intermediate care and skilled nursing home’ were classified as 17 
moderate-to-severe disability on discharge.  18 
2.3 Statistical Analysis 19 
 All analyses were performed using Stata 15.1SE, Stata Statistical Software. A 1% 20 
threshold of statistical significance was utilised for all analyses (P < 0.01). All analyses were 21 
performed according to the Healthcare Cost and Utilisation Project (HCUP) guidelines31, 22 





































































techniques stratifying by NIS stratum and year of admission32 in order to account for patient 1 
clustering within hospitals and produce US-wide estimates33,34. 2 
2.3.1 Descriptive Statistics 3 
 Patient characteristics were compared across the 4 exposure categories using either 4 
the χ2 test or ANOVA, as appropriate. The yearly prevalence of each exposure category and 5 
the yearly rates of IVT and ET therapy were computed. The yearly rates of IVT and ET 6 
therapy were also computed for different exposure categories.  7 
2.3.2 Primary Analyses 8 
 In order to determine whether patients with AF, HF or AF+HF have improved AIS in-9 
hospital outcomes with IVT and ET, multivariable logistic regressions were performed 10 
modelling the association between the exposure groups and outcomes, using the neither AF 11 
nor HF group as a reference category and including interaction terms with IVT and ET. The 12 
regression models were also stratified based on whether received IVT or ET therapy. The 13 
models were adjusted for the covariates listed below. 14 
2.3.3 Secondary and Post-hoc analyses 15 
 Multivariable logistic regressions were performed modelling the association between 16 
exposure groups and the odds of receiving IVT or ET therapy, using the neither AF nor HF 17 
group as a reference category. Furthermore, based on the results of the primary analyses, 18 
further post-hoc logistic regression models were performed evaluating the relationship 19 
between IVT/ET therapy and outcomes, stratified by exposure groups. The models were 20 
adjusted for the covariates listed below. 21 





































































All models were adjusted for age, sex, ethnicity, smoking status, hospital 1 
characteristics (bed size, location, teaching status), 28 Elixhauser comorbidities (human 2 
immunodeficiency virus infection/acquired immune deficiency syndrome, alcohol abuse, 3 
anemia (deficiency and blood loss), rheumatoid arthritis/collagen vascular disease, chronic 4 
pulmonary disease, coagulopathy, depression, diabetes mellitus (with and without 5 
complications), drug abuse, hypertension, hypothyroidism, liver disease, lymphoma, fluid & 6 
electrolyte disorders, metastatic cancer, other neurological disorders, obesity, paralysis, 7 
peripheral vascular disease, psychosis, pulmonary circulation disorders, renal failure, solid 8 
tumour (without metastasis), peptic ulcer disease, valvular disease, weight loss) and other co-9 
morbidities (myocardial infarction, coronary heart disease, arrhythmias other than AF, 10 
dyslipidaemia, previous transient ischaemic attack, dementia, shock), previous coronary 11 
artery bypass surgery, and family history of cerebrovascular events or ischaemic heart 12 
disease. The Elixhauser co-morbidities were included as individual co-variates. Adjusting co-13 
variates were selected based on clinical judgement and previous literature3,5-7. 14 
3. Results 15 
3.1 Descriptive Statistics 16 
 Table 1 and Supplementary Table 2 summarise the patient characteristics on 17 
admission in brief and in full, respectively. Out of 4,597,428 AIS patients, there were 18 
3,182,285 (69.22%) patients with neither AF nor HF, 761,856 (16.59%) patients with AF 19 
only, 346,482 (7.54%) patients with HF only and 305,805 (6.65%) patients with AF+HF. The 20 
median (inter-quartile range) age of the included cohort was 73 (61-83) years. The median 21 
length-of-stay (LoS) was 4 (2-6) days. There were 52.79% females. Patients with AF only, 22 
HF only or AF+HF had more co-morbidities (other than AF or HF) than those with neither 23 
AF nor HF. There were 231,606 (5.04%) and 33,173 (0.72%) AIS patients undergoing IVT 24 





































































with neither AF nor HF, AF only, HF only and AF+HF the mortality rates were 3.24%, 1 
7.90%, 7.60% and 11.97%, respectively. There were 2,709,450 (62.51%) patients with 2 
moderate-to-severe discharge disability. A total of 145,927 (3.17%) patients suffered all-3 
cause bleeding. 4 
Supplementary Table 3 summarises the patient characteristics for the patient sample 5 
undergoing IVT. AIS patients undergoing IVT had a median (IQR) age of 71 (59-81) years, 6 
median (IQR) LoS 5 (3-7) days and were 49.94% females. A total of 16,084 (6.94%) AIS 7 
patients undergoing IVT also underwent ET, which constitutes 48.48% of the population of 8 
AIS patients undergoing ET. For AIS patients undergoing IVT, the overall in-hospital 9 
mortality rate was 8.45%. There were 139,457 (66.33%) patients discharged with a moderate-10 
to-severe discharge disability. A total of 27284 (11.78%) patients suffered in-hospital 11 
bleeding. Supplementary Table 4 summarises the patient characteristics for the patient sample 12 
undergoing ET. AIS patients undergoing ET had a median (IQR) age of 69 (58-79) years, 13 
median (IQR) LoS 7 (4-11) days and were 49.62% females. For AIS patients undergoing ET, 14 
the overall in-hospital mortality rate was 16.66%. There were 22,399 (81.17%) patients 15 
discharged with a moderate-to-severe discharge disability. A total of 8896 (26.82%) AIS 16 
patients undergoing ET suffered all-cause bleeding. 17 
Figure 2 summarises the estimated yearly prevalence of the exposure groups between 18 
2004-2015. The estimated prevalence of AF without HF increased steadily between 2004 and 19 
2011 from 14.2% to 17.7%, after which it reached a plateau until 2015 at ~17.8%. The 20 
estimated prevalence of HF without AF was ~7.3-7.9% throughout 2004-2015. The estimated 21 
prevalence of AF+HF was ~6.5% between 2004 and 2010, increasing steadily between 2010 22 
and 2015 to 7.3%. Figure 2 also summarises the estimated yearly rates of IVT and ET 23 
between 2004-2015. The IVT rate increased steadily between 2004 (1.65%) and 2015 24 





































































Supplementary Figure 1 and Supplementary Table 5 summarise the estimated yearly 1 
rates of IVT and ET therapy stratified by the exposure groups. The IVT and ET rates were 2 
significantly higher amongst patients with AF only and AF+HF than in patients with HF only 3 
or neither AF nor HF throughout the study period. 4 
 5 
 6 
3.2 Primary Analyses 7 
 Figure 3 and Supplementary Table 6 detail the results of the primary analyses. 8 
Supplementary Table 7 details the effect size of the interactions between revascularisation 9 
therapies and the relationship between the exposures of interest and in-hospital outcomes. 10 
Amongst patients not receiving IVT, AF only (1.90 (1.83-1.96)), HF only ((1.81 (1.72-1.89)) 11 
and AF+HF (2.63 (2.51-2.75)) were associated with increased odds of in-hospital mortality. 12 
Amongst patients receiving IVT, AF only (1.43 (1.28-1.58)), HF only (1.35 (1.13-1.60)) and 13 
AF+HF (1.72 (1.49-1.99)) were associated with increases in the odds of in-hospital mortality 14 
which were significantly lower than the increases recorded amongst patients not undergoing 15 
IVT (P value for interaction <0.001). Thus, IVT was associated with 25% decreases in the 16 
AF-only and HF-only associated increases in the odds of in-hospital mortality, while a 35% 17 
decrease was recorded in AF+HF patients. AF only, HF only and AF+HF were associated 18 
with significant increases in the odds of prolonged hospitalisation amongst both the IVT and 19 
no IVT groups. The increases in the odds of prolonged hospitalisation associated with AF 20 
only and AF+HF, but not HF only, were significantly higher amongst patients undergoing 21 
IVT than in those not undergoing IVT (P value for interaction ≤0.001). AF only, HF only and 22 
AF+HF were associated with significant increases in the odds of moderate-to-severe 23 





































































AF+HF were associated with significant increases in the odds of all-cause bleeding amongst 1 
both the IVT and no IVT groups. The increases in the odds of all-cause bleeding associated 2 
with AF only and AF+HF were significantly lower amongst patients undergoing IVT than in 3 
those not undergoing IVT (P value for interaction ≤0.001).  4 
 Amongst patients not receiving ET, AF only (1.88 (1.82-1.95)), HF only ((1.79 (1.71-5 
1.88)) and AF+HF (2.58 (2.47-2.70)) were associated with increased odds of in-hospital 6 
mortality. Amongst patients receiving ET, AF only (0.75 (0.60-0.93)) was associated with 7 
decreased odds of in-hospital mortality. There were no associations between HF only (0.73 8 
(0.49-1.10)) or AF+HF (0.88 (0.64-1.12)) and in-hospital mortality amongst patients 9 
undergoing ET. Thus, ET was associated with 60% decreases in the AF-only and HF-only 10 
associated increases in the odds of in-hospital mortality, while a  66% decrease was recorded 11 
in AF+HF patients. Amongst patients not receiving ET, AF only, HF only and AF+HF were 12 
associated with increased odds of prolonged hospitalisation, moderate-to-severe disability on 13 
discharge and all-cause bleeding. There were no associations between the exposure groups 14 
and prolonged hospitalisation, moderate-to-severe disability on discharge or all-cause 15 
bleeding amongst patients undergoing ET. 16 
3.3 Secondary and Post-hoc analyses 17 
  Supplementary Table 87 details the associations between exposure groups and the 18 
odds of receiving IVT or ET. Compared to patients with neither AF nor HF, patients with AF 19 
only (Odds Ratio (99% CI) = 1.43 (1.37-1.49)), HF only (1.13 (1.06-1.20)) and AF+HF (1.38 20 
(1.30-1.48)) were more likely to receive IVT. Similarly, compared to patients with neither 21 
AF nor HF, those with AF only (2.48 (2.26-2.73)), HF only (1.28 (1.11-1.48)) and AF+HF 22 
(2.55 (2.25-2.90)) were more likely to receive ET. Supplementary Table 98 details the results 23 





































































of in-hospital mortality amongst patients with neither AF nor HF than in those with AF only, 1 
HF only or AF+HF. IVT was associated with higher increases in the odds of all-cause 2 
bleeding amongst patients with neither AF nor HF, AF only and HF only than in those with 3 
AF+HF. ET was associated with a higher increase in the odds of all-cause bleeding amongst 4 
patients with neither AF nor HF than in those with AF only, HF only or AF+HF. 5 
 6 
4. Discussion 7 
 In this analysis of a sample representative of over 4.5 million AIS admissions, we 8 
have found that co-existent AF and HF were associated with more than two-fold increased 9 
odds of in-hospital mortality, whilst AF only and HF only were each associated with 75-85% 10 
increases, suggesting that the excess odds associated  with either AF or HF in isolation may 11 
be cumulative when the two co-exist. Similar relationships were delineated between the 12 
exposure groups and the excess odds of prolonged hospitalisation and moderate-to-severe 13 
disability on discharge. Nevertheless, the same effect was not observed for the all-cause 14 
bleeding outcome: AF only and AF+HF were associated with ~80-90% increase in the odds 15 
of all-cause bleeding, while HF only was only associated with a 33% increase. This is likely 16 
reflective of the fact that AF patients are more likely to receive anticoagulant therapy than 17 
patients in sinus rhythm35. 18 
   19 
IVT therapy was associated with significant reductions in the excess odds of in-20 
hospital mortality and all-cause bleeding associated with AF and AF+HFall exposure groups. 21 
Nevertheless, higher reductions in excess in-hospital mortality associated with IVT were 22 
recorded in patients with AF+HF than in those with either AF only or HF only. IVT was 23 





































































associated with AF and AF+HF. Post-hoc analyses aimed at further characterising this 1 
finding revealed that this may be because IVT was associated with higher odds of bleeding in 2 
all AIS patients, but the IVT-associated excess odds of bleeding were significantly higher 3 
amongst patients with neither AF nor HF than in those with AF only or AF+HF. Given that 4 
prior anticoagulation is a contra-indication to IVT36, this finding may be due to the fact that 5 
only AF patients without prior anticoagulant therapy may have been offered IVT, resulting in 6 
an overall lower bleeding risk amongst these patients. IVT therapy was associated with 7 
significant reductions in the excess odds of all-cause bleeding associated with AF and 8 
AF+HF. Our results also show that AIS patients with co-morbid HF undergoing IVT were at 9 
lower odds of in-hospital mortality and similar odds of discharge disability and all-cause 10 
bleeding compared to their counterparts not undergoing IVT. Out of all the studied outcomes 11 
in relation to IVT therapy, discharge disability showed the weakest associations. However, it 12 
is important to consider when interpreting these results that we defined discharge disability as 13 
a proxy based on discharge destination.   14 
ET was associated with significant reductions in the AF- and AF+HF-associated 15 
excess odds of in-hospital mortality, discharge disability and all-cause bleeding. Furthermore, 16 
ET was also associated with significant reductions in the HF-associated excess odds of in-17 
hospital mortality and all-cause bleeding. Similarly as with IVT, higher reductions in excess 18 
in-hospital mortality associated with ET were recorded in patients with AF+HF than in those 19 
with either AF only or HF only.  Amongst AIS patients undergoing ET, AF was associated 20 
with decreased odds of in-hospital mortality whilst there were no other associations between 21 
AF, HF or AF+HF and any other pre-specified outcomes. Post-hoc analyses revealed that 22 
these findings may be because ET disproportionately increased the odds of adverse outcomes 23 
amongst AIS patients with neither AF nor HF, but not amongst those with AF or HF. Having 24 





































































factors such the stroke subtype or stroke pre-functional status may explain these findings. 1 
Thus, these differences may be attributable to previous findings that ET may be more 2 
effective at achieving reperfusion and subsequently better post-stroke outcomes in 3 
cardioembolic stroke subtypes37, which tend to occur more commonly amongst patients with 4 
co-morbid AF or HF38. Furthermore, current AHA/ASA guidelines recommend that only 5 
patients with an excellent pre-stroke functional status (mRS ≤ 1) should be offered ET 6 
therapy36, resulting in the selection of only those patients with lower severity of cardiac co-7 
morbidities, which could partly explain the lack of association between AF or HF and any 8 
adverse outcomes amongst AIS patients undergoing ET.  9 
Our secondary analyses showed that AIS patients with co-morbid AF, regardless of 10 
whether HF co-existed, were 40% more likely to receive IVT therapy and more than twice as 11 
likely to receive ET therapy in hospital. Yearly analyses also revealed that these patterns 12 
remained constant amid the increasing uptake of IVT and ET during AIS admissions and an 13 
increasing prevalence of AF between 2004 and 2015. This highlights the fact that patients 14 
with co-morbid AF or HF were more likely to receive evidence-based reperfusion therapy 15 
under current clinical practice since the widespread adoption of IVT and ET for emergency 16 
AIS management in the United States. It could be that the association between co-morbid AF 17 
and ET therapy for AIS may be at least partly driven by the fact that AF patients are more 18 
likely to suffer large artery occlusion strokes39 and thus more likely candidates for ET than 19 
patients without AF. 20 
 Previous studies assessing revascularisation strategies amongst AIS patients with AF 21 
or HF have reached equivocal results. A meta-analysis showed that AF was associated with 22 
adverse post-AIS outcomes amongst patients receiving IVT: there was a significant 23 
association only with increased 90-day mortality and stroke-related disability, but not in-24 





































































with increased 90-day stroke-related disability and symptomatic intracranial haemorrhage 1 
rates amongst AIS patients undergoing IVT12,13. Several other observational studies have 2 
nevertheless failed to show the same relationships amongst these patients16,17,20,21. A 3 
retrospective analysis of pooled clinical trial data including more than 5,000 patients 4 
concluded that whilst HF was associated with adverse outcomes in patients with AIS 5 
undergoing IVT, those patients had nevertheless significantly better outcomes compared to 6 
AIS patients with co-morbid HF who did not undergo IVT15. It has also been previously 7 
found that ET for large artery occlusion stroke did not improve the outcomes of patients with 8 
co-morbid AF23, whilst another study has found that HF may not be associated with excess 9 
mortality or disability after ET for large artery occlusion AIS25.  10 
 Our findings may thus provide more clarity regarding the relationship between 11 
recanalization strategies in ischaemic stroke and these common co-morbid conditions. The 12 
several strengths of our study, such as the large sample size representative of all AIS patients 13 
admitted to US hospitals, the wide range of confounders included as adjusting factors in all 14 
analyses as well as considering patients with co-existent AF and HF as a separate group, 15 
allow the derivation of several clinical implications. Overall, patients with AF or HF 16 
undergoing IVT had either better or at least similar in-hospital outcomes compared to their 17 
counterparts not receiving IVT, suggesting that solely co-morbid AF and/or HF should not 18 
represent a discriminating factor in the decision of whether emergency IVT should be 19 
administered to AIS patients. Furthermore, our results pertaining to ET therapy are 20 
particularly encouraging and complement previous findings suggesting that ET therapy is 21 
efficacious and safe amongst AIS patients with co-morbid AF23 or HF25.  22 
 We acknowledge certain limitations. Given the nature of the National Inpatient 23 
Sample, the ascertainment of exposure groups, co-morbidities, procedures and the all-cause 24 





































































using ICD-9 codes, these were not validated against clinical data due to lack of this 1 
information. It is thus likely that some asymptomatic episodes of paroxysmal AF may not 2 
have been captured in the absence of continuous cardiac monitoring in at-risk patients. 3 
Nevertheless, our study reflects real-world clinical practice in which continuous cardiac 4 
monitoring is not routinely performed with the exception patients with cryptogenic stroke or 5 
with pacemakers/implantable cardioverter/defibrillators40. Our data also lacked stroke 6 
severity measures such as the National Institute of Health Stroke Scale (NIHSS) or the pre- 7 
and post-stroke modified Rankin Scale (mRS). Thus, we were unable to perform analyses 8 
evaluating outcomes of stroke severity. Nevertheless, we used the patient discharge 9 
destination (discharges to ‘home health care’, ‘short-term hospital’ and ‘other facilities 10 
including intermediate care and skilled nursing home’) as a proxy for moderate-to-severity 11 
disability on discharge in our analyses, which has been previously validated30. This measure 12 
has been estimated to yield a positive predictive value of 90% of an mRS score of 2-6 at 3 13 
months post-stroke30. Furthermore, in the absence of stroke severity data, we were also 14 
unable to fully adjust for selection bias in assigning IVT/ET treatment, which may be driven 15 
by differences in stroke severity as well as patient demographics and comorbidities between 16 
treatment groups. Due to the fact that the application of propensity score matching analyses is 17 
yet unclear in the context of complex survey design41, we have chosen not to perform 18 
propensity score matching and we were thus unable to ensure that the treated and untreated 19 
groups were balanced in terms of measured confounders. Nevertheless, given our large 20 
sample size and number of events per covariate, we deemed traditional covariate adjustment 21 
an appropriate alternative42. Thus, having adjusted our logistic regression analyses for age, 22 
sex, ethnicity and a wide range of co-morbid conditions it is likely that these adjustments 23 
partly accounted for such biases. However, residual confounding cannot be eliminated given 24 





































































limitation. Due to unavailable data, we were unable to account for the time from stroke onset 1 
to receipt of revascularisation therapy in our analyses. Nevertheless, according to current 2 
guidelines, only patients presenting within 4.5h and 6h of stroke onset are eligible to receive 3 
intravenous thrombolysis or endovascular thrombectomy, respectively36. Therefore, it is 4 
likely that the time from stroke onset may have little influence on the overall patient-related 5 
outcomes to the extent to which clinical guidelines guiding the timing of revascularisation 6 
therapy were followed. Our study lacks post-discharge follow-up data, which did not allow 7 
the analysis of long-term outcomes. Finally, our analyses only included admissions up to 8 
September 2015 and it should be noted that ET has only emerged as an evidence-based 9 
emergency therapy for AIS in 201543. However, this is unlikely to impact the reliability of 10 
our analysis assessing the relationship between exposure groups and AIS outcomes in 11 
patients receiving ET. Nevertheless, our findings pertaining to ET therapy should also be 12 
confirmed in future research on data including more AIS cases admitted after 2015. 13 
 14 
5. Conclusions 15 
 In this study of real-world data, AIS patients with co-morbid AF or HF undergoing 16 
IVT had either better or comparable in-hospital adverse outcomes than their counterparts 17 
not undergoing IVT. There were no positive associations between AF or HF and adverse 18 
in-hospital outcomes amongst AIS patients undergoing ET. Therefore, Cco-morbid AF 19 
and/or HF should not solely represent a criterion against delivering IVT therapy to AIS 20 
patients. Furthermore,, while ET may be an effective therapeutic strategy to manage the 21 
excess risk of adverse short-term outcomes associated with AF and/or HF in AIS. 22 
Therefore, revascularisation therapies should be considered and offered routinely in acute 23 
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Table 1. Descriptive statistics of the entire included sample. Further descriptive statistics are detailed in Supplementary Table 2. 
 
 No AF/No HF AF only HF only AF and HF Total P value 
N 3182285 762856 346482 305805 4597428  
PATIENT CHARACTERISTICS 
Age 69.00 (58.00-80.00) 81.00 (73.00-87.00) 75.00 (63.00-84.00) 82.00 (75.00-88.00) 73.00 (61.00-83.00) < 0.001 
Length of stay (days) 3.00 (2.00-6.00) 4.00 (3.00-7.00) 5.00 (3.00-7.00) 5.00 (3.00-8.00) 4.00 (2.00-6.00) < 0.001 
Sex (Female) 1615220 (50.76) 443521 (58.14) 185520 (53.54) 182591 (59.71) 2426852 (52.79) < 0.001 
Ethnicity      < 0.001 
White 1833364 (57.61) 536844 (70.37) 187891 (54.23) 208072 (68.04) 2766172 (60.17)  
Black 497102 (15.62) 51952 (6.81) 71704 (20.69) 29959 (9.80) 650717 (14.15)  
Hispanic 222686 (7.00) 36451 (4.78) 21220 (6.12) 14602 (4.77) 294958 (6.42)  
Asian or Pacific 
Islander 75368 (2.37) 18604 (2.44) 5585 (1.61) 5314 (1.74) 104871 (2.28) 
 
Native American 13755 (0.43) 1951 (0.26) 1718 (0.50) 854 (0.28) 18278 (0.40)  
Other 71013 (2.23) 14441 (1.89) 6997 (2.02) 5754 (1.88) 98205 (2.14)  
Missing 468997 (14.74) 102613 (13.45) 51367 (14.83) 41251 (13.49) 664227 (14.45)  
ELIXHAUSER CO-MORBIDITIES 
HIV/AIDS 7545 (0.24) 283 (0.04) 608 (0.18) 101 (0.03) 8537 (0.19) < 0.001 
Alcohol Abuse 144140 (4.53) 19314 (2.53) 10850 (3.13) 6668 (2.18) 180972 (3.94) < 0.001 
Deficiency anaemia 323057 (10.15) 90127 (11.81) 61276 (17.69) 52686 (17.23) 527145 (11.47) < 0.001 
Rheumatoid 
Arthritis/Collagen 
Vascular Disease 75732 (2.38) 18789 (2.46) 8543 (2.47) 7591 (2.48) 110655 (2.41) 
0.1 
Chronic blood loss 
anaemia 11675 (0.37) 3868 (0.51) 2312 (0.67) 2478 (0.81) 20333 (0.44) 
< 0.001 
Chronic Pulmonary 






































































Coagulopathy 77853 (2.45) 25881 (3.39) 12741 (3.68) 13354 (4.37) 129830 (2.82) < 0.001 
Depression 310547 (9.76) 62214 (8.16) 33835 (9.77) 25238 (8.25) 431833 (9.39) < 0.001 
Diabetes Mellitus, 
Uncomplicated 921666 (28.96) 180367 (23.64) 118374 (34.16) 83378 (27.27) 1303785 (28.36) 
< 0.001 
Diabetes Mellitus, 
Chronic Complications 185401 (5.83) 28850 (3.78) 38537 (11.12) 18051 (5.90) 270839 (5.89) 
< 0.001 
Drug abuse 87892 (2.76) 4206 (0.55) 8925 (2.58) 2169 (0.71) 103192 (2.24) < 0.001 
Hypertension 2524436 (79.33) 616107 (80.76) 280859 (81.06) 237404 (77.63) 3658807 (79.58) < 0.001 
Hypothyroidism 352723 (11.08) 125783 (16.49) 45538 (13.14) 53222 (17.40) 577267 (12.56) < 0.001 
Liver Disease 35698 (1.12) 6035 (0.79) 4702 (1.36) 3387 (1.11) 49822 (1.08) < 0.001 
Lymphoma 15223 (0.48) 4158 (0.55) 2103 (0.61) 1992 (0.65) 23476 (0.51) 0.3 
Fluid and Electrolyte 
Disorders 580279 (18.23) 166351 (21.81) 91010 (26.27) 84336 (27.58) 921976 (20.05) 
< 0.001 
Metastatic Cancer 48412 (1.52) 9277 (1.22) 4151 (1.20) 2771 (0.91) 64611 (1.41) < 0.001 
Other Neurological 
Disorders 13016 (0.41) 4446 (0.58) 3031 (0.87) 2408 (0.79) 22901 (0.50) 
< 0.001 
Obesity 269379 (8.46) 45743 (6.00) 37222 (10.74) 22283 (7.29) 374627 (8.15) < 0.001 
Paralysis 103312 (3.25) 47289 (6.20) 15487 (4.47) 19174 (6.27) 185261 (4.03) < 0.001 
Peripheral Vascular 
Disease 266993 (8.39) 65072 (8.53) 41089 (11.86) 32705 (10.69) 405859 (8.83) 
< 0.001 
Psychosis 104710 (3.29) 17108 (2.24) 11523 (3.33) 7310 (2.39) 140651 (3.06) < 0.001 
Pulmonary Circulation 
Disorders 47601 (1.50) 34644 (4.54) 20056 (5.79) 30798 (10.07) 133099 (2.90) 
< 0.001 
Renal Failure 306169 (9.62) 89366 (11.71) 90198 (26.03) 69413 (22.70) 555147 (12.08) < 0.001 
Solid Tumour (without 
metastasis) 51734 (1.63) 14810 (1.94) 5659 (1.63) 5487 (1.79) 77690 (1.69) 
< 0.001 
Peptic Ulcer Disease 
(excluding bleeding) 849 (0.03) 303 (0.04) 129 (0.04) 131 (0.04) 1411 (0.03) 
< 0.001 
Valvular Disease 226197 (7.11) 118171 (15.49) 50235 (14.50) 70312 (22.99) 464915 (10.11) < 0.001 
PROCEDURES 





































































Echocardiography 425188 (13.36) 75225 (9.86) 39687 (11.45) 26467 (8.65) 566567 (12.32) < 0.001 
Thrombectomy 15580 (0.49) 10826 (1.42) 2376 (0.69) 4390 (1.44) 33173 (0.72) < 0.001 
OUTCOMES 
In-Hospital Mortality 103173 (3.24) 60251 (7.90) 26319 (7.60) 36606 (11.97) 226349 (4.92) < 0.001 
Los > Median 1116073 (35.07) 369734 (48.47) 175472 (50.64) 172516 (56.41) 1833795 (39.89) < 0.001 
Discharge Disability 1737314 (56.97) 520104 (74.37) 230580 (72.57) 221452 (82.68) 2709450 (62.51) < 0.001 











































































Figure 1. Patient Population Flowchart 








































































Figure 2. A: Yearly prevalence (2004-2015) of AF, HF and AF+HF amongst AIS patients in 
the National Inpatient Sample. B: Yearly rates (2004-2015) of intravenous thrombolysis and 
endovascular thrombectomy during acute ischaemic stroke admissions in the National 
Inpatient Sample. 










































































Figure 3. Results of the logistic regressions modelling the associations between co-morbidity 
status (no AF and no HF; AF only; HF only; AF+HF) and in-hospital outcomes amongst all 
AIS patients, stratified by whether patients received IVT (A) or ET (B) therapy. The odds 
ratios are displayed alongside the P values corresponding to the interaction term between 
IVT/ET and co-morbidity status. The no AF and no HF group was used as reference. All 
models were adjusted for age, sex, ethnicity, smoking status, hospital characteristics (bed 
size, location, teaching status), 28 Elixhauser co-morbidities and other co-morbidities 
(myocardial infarction, coronary heart disease, other arrhythmias, dyslipidaemia, previous 
transient ischaemic attack, dementia, shock), previous coronary artery bypass surgery, and 
family history of cerebrovascular events or ischaemic heart disease. 
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